NeoPharm CO., LTD. (092730.KQ)

KRW 11960.0

(-0.33%)

Total Liabilities Summary of NeoPharm CO., LTD.

NeoPharm CO., LTD.'s latest annual total liabilities in 2023 was 19.3 Billion KRW , up 46.98% from previous year.
NeoPharm CO., LTD.'s latest quarterly total liabilities in 2024 Q1 was 25.03 Billion KRW , up 29.68% from previous quarter.
NeoPharm CO., LTD. reported annual total liabilities of 13.13 Billion KRW in 2022, up 0.26% from previous year.
NeoPharm CO., LTD. reported annual total liabilities of 13.1 Billion KRW in 2021, down -14.14% from previous year.
NeoPharm CO., LTD. reported quarterly total liabilities of 25.03 Billion KRW for 2024 Q1, up 29.68% from previous quarter.
NeoPharm CO., LTD. reported quarterly total liabilities of 18.87 Billion KRW for 2023 Q1, up 43.7% from previous quarter.

Annual Total Liabilities Chart of NeoPharm CO., LTD. (2023 - 2012)

Historical Annual Total Liabilities of NeoPharm CO., LTD. (2023 - 2012)

Year	Total Liabilities	Total Liabilities Growth
2023	19.3 Billion KRW	46.98%
2022	13.13 Billion KRW	0.26%
2021	13.1 Billion KRW	-14.14%
2020	15.26 Billion KRW	-10.49%
2019	17.04 Billion KRW	24.98%
2018	13.64 Billion KRW	49.69%
2017	9.11 Billion KRW	14.8%
2016	7.93 Billion KRW	1.96%
2015	7.78 Billion KRW	0.0%
2012	3.3 Billion KRW	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	17.66 Billion KRW	-36.74%
2024 Q1	25.03 Billion KRW	29.68%
2023 Q1	18.87 Billion KRW	43.7%
2023 FY	19.3 Billion KRW	46.98%
2023 Q4	19.3 Billion KRW	26.58%
2023 Q3	15.25 Billion KRW	21.06%
2023 Q2	12.59 Billion KRW	-33.26%
2022 Q3	10.62 Billion KRW	-18.91%
2022 Q1	19.16 Billion KRW	46.3%
2022 FY	13.13 Billion KRW	0.26%
2022 Q4	13.13 Billion KRW	23.66%
2022 Q2	13.09 Billion KRW	-31.67%
2021 Q4	13.1 Billion KRW	-16.76%
2021 Q1	22.58 Billion KRW	47.97%
2021 FY	13.1 Billion KRW	-14.14%
2021 Q2	16.16 Billion KRW	-28.43%
2021 Q3	15.74 Billion KRW	-2.6%
2020 FY	15.26 Billion KRW	-10.49%
2020 Q4	15.26 Billion KRW	13.04%
2020 Q2	15.37 Billion KRW	-31.76%
2020 Q3	13.49 Billion KRW	-12.17%
2020 Q1	22.52 Billion KRW	32.12%
2019 Q3	11.11 Billion KRW	-11.58%
2019 Q1	14.96 Billion KRW	9.74%
2019 FY	17.04 Billion KRW	24.98%
2019 Q4	17.04 Billion KRW	53.42%
2019 Q2	12.56 Billion KRW	-16.04%
2018 Q2	8.88 Billion KRW	-23.77%
2018 FY	13.64 Billion KRW	49.69%
2018 Q1	11.65 Billion KRW	29.25%
2018 Q4	13.64 Billion KRW	48.68%
2018 Q3	9.17 Billion KRW	3.29%
2017 Q1	8.36 Billion KRW	7.84%
2017 FY	9.11 Billion KRW	14.8%
2017 Q4	9.01 Billion KRW	50.29%
2017 Q3	5.99 Billion KRW	3.49%
2017 Q2	5.79 Billion KRW	-30.71%
2016 Q2	4.03 Billion KRW	0.0%
2016 Q4	7.75 Billion KRW	103.44%
2016 Q3	3.81 Billion KRW	-5.6%
2016 Q1	- KRW	-100.0%
2016 FY	7.93 Billion KRW	1.96%
2015 Q4	7.38 Billion KRW	0.0%
2015 FY	7.78 Billion KRW	0.0%
2013 Q2	3.87 Billion KRW	24.36%
2013 Q3	3.54 Billion KRW	-8.5%
2013 Q1	3.11 Billion KRW	-5.76%
2012 Q4	3.3 Billion KRW	0.0%
2012 FY	3.3 Billion KRW	0.0%

Peer Total Liabilities Comparison of NeoPharm CO., LTD.

Name	Total Liabilities	Total Liabilities Difference
Kolmar BNH Co., Ltd.	298.2 Billion KRW	93.525%